Zarogoulidis Paul, Gaga Mina, Huang Haidong, Darwiche Kaid, Rapti Aggeliki, Hohenforst-Schmidt Wolfgang
Pulmonary Department-Oncology Unit, ``G. Papanikolaou`` General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
7th Respiratory Medicine Department and Asthma Center, Athens Chest Hospital 'Sotiria', Athens, Greece.
Clin Transl Med. 2017 Dec;6(1):6. doi: 10.1186/s40169-017-0135-8. Epub 2017 Jan 18.
Lung cancer is still the leading cause of death among all cancers. During the last 15 years, pharmacogenomics of lung cancer have established targeted therapy with tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) positive patients in adenocarcinoma or mixed adenosquamus lung cancer patients. However; while novel drugs are released in the market, at the same time novel mutations are observed after tyrosine kinase inhibitor administration. Recently the novel mutation T790 was observed and is highly prevalent in patients already treated with a TKI. A new drug targeting this mutation is already on the market, however; the most important factor for successful treatment in these patients, is adequate tissue re-sampling so that novel mutations can be detected.
肺癌仍是所有癌症中导致死亡的首要原因。在过去15年里，肺癌的药物基因组学已确立了针对腺癌或腺鳞混合性肺癌中表皮生长因子受体（EGFR）阳性患者使用酪氨酸激酶抑制剂（TKIs）进行靶向治疗。然而，在市场上有新药推出的同时，酪氨酸激酶抑制剂给药后也出现了新的突变。最近发现了新的T790突变，在已经接受过TKI治疗的患者中非常普遍。一种针对该突变的新药已上市，然而，这些患者成功治疗的最重要因素是进行充分的组织重新取样，以便能够检测到新的突变。
